AMR Declaration
15 November, 2017
Declaration by the In Vitro Diagnostics Industry on Tackling Antimicrobial Resistance – signed by Mr Belingard, Chairman of bioMérieux November 2017
bIoMerieux and COPAN Distribution Agreement Extended to Ireland
17 November, 2015
BioFire FilmArray® Meningitis Panel FDA clearance
19 October, 2015
BioFire Receives FDA Clearance for the FilmArray® 2.0 System
26 February, 2015
New system delivers higher throughput, single database management and minimized footprint
Strategic alliance between bioMérieux and COPAN
14 January, 2015
BioFire Defense, a bioMérieux company, receives fast-track authorization of FilmArray® Ebola Test
27 October, 2014
Marcy l’Etoile (France) - October 27, 2014 - BioFire Defense, LLC of Salt Lake City, UT announced today that it has received Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) for its commercial FilmArray® Ebola test (BioThreat-E test™).
bioMérieux VIRTUO™, the new generation of blood culture system, is CE-marked
23 July, 2014
Marcy l'Etoile, France, July 23, 2014 - bioMérieux, a world leader in the field of in vitro diagnostics, announces that VIRTUO™, the new generation of BacT/ALERT®, has been CE-marked. This uniquely innovative automated blood culture microbial detection system further enriches the offering of the BacT/ALERT® product range and is now commercially available in targeted countries that recognize CE marking. The enhanced performance of the system will help laboratories provide rapid results to clinicians to help maximize laboratory efficiency and facilitate better patient outcomes.